[
  {
    "ts": null,
    "headline": "Hologic, Inc. (HOLX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript",
    "summary": "Get key insights on Hologic's growth strategy, innovation in diagnostics and breast health",
    "url": "https://finnhub.io/api/news?id=2f6aab56f95b590f22dde5427b43289da3b435083d875fda7194d79b15b2a6c9",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757426751,
      "headline": "Hologic, Inc. (HOLX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript",
      "id": 136678383,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "HOLX",
      "source": "SeekingAlpha",
      "summary": "Get key insights on Hologic's growth strategy, innovation in diagnostics and breast health",
      "url": "https://finnhub.io/api/news?id=2f6aab56f95b590f22dde5427b43289da3b435083d875fda7194d79b15b2a6c9"
    }
  },
  {
    "ts": null,
    "headline": "US STI testing sales drop amid “multifactorial” causes",
    "summary": "GlobalData analysis reveals that in H1 2025, sales volume for chlamydia/gonorrhoea tests across US healthcare sites and other facilities decreased by 1.7% versus H1 2024, and by 27.8% for tests targeting bacterial vaginosis.",
    "url": "https://finnhub.io/api/news?id=965a323669e41f4f812b3722c135b9e6b2335e0f8ac02617e4ee8a0c5197c5eb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757419443,
      "headline": "US STI testing sales drop amid “multifactorial” causes",
      "id": 136775049,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "HOLX",
      "source": "Yahoo",
      "summary": "GlobalData analysis reveals that in H1 2025, sales volume for chlamydia/gonorrhoea tests across US healthcare sites and other facilities decreased by 1.7% versus H1 2024, and by 27.8% for tests targeting bacterial vaginosis.",
      "url": "https://finnhub.io/api/news?id=965a323669e41f4f812b3722c135b9e6b2335e0f8ac02617e4ee8a0c5197c5eb"
    }
  },
  {
    "ts": null,
    "headline": "US hospital STI testing sales drop amid “multifactorial” causes",
    "summary": "GlobalData analysis reveals that in H1 2025, US hospital sales volume for chlamydia/gonorrhoea tests decreased by 1.7% versus H1 2024, and by 27.8% for tests targeting bacterial vaginosis.",
    "url": "https://finnhub.io/api/news?id=e01ab3e62f6f2b3e2df50bbe4a904447d953190e609de11779907624b52772af",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757419443,
      "headline": "US hospital STI testing sales drop amid “multifactorial” causes",
      "id": 136690960,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "HOLX",
      "source": "Yahoo",
      "summary": "GlobalData analysis reveals that in H1 2025, US hospital sales volume for chlamydia/gonorrhoea tests decreased by 1.7% versus H1 2024, and by 27.8% for tests targeting bacterial vaginosis.",
      "url": "https://finnhub.io/api/news?id=e01ab3e62f6f2b3e2df50bbe4a904447d953190e609de11779907624b52772af"
    }
  }
]